Skip to main navigation
Skip to search
Skip to main content
Aston Research Explorer Home
Help & FAQ
Home
Research units
Profiles
Research Outputs
Datasets
Student theses
Activities
Press/Media
Prizes
Equipment
Search by expertise, name or affiliation
Clinical anticachexia treatments
Michael J. Tisdale
*
*
Corresponding author for this work
Aston Pharmacy School
College of Health and Life Sciences
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Clinical anticachexia treatments'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Agriculture & Biology
cachexia
100%
clinical examination
21%
protein degradation
19%
skeletal muscle
16%
megestrol
16%
protein synthesis
13%
cyclooxygenase inhibitors
12%
cannabinoids
12%
quality of life
10%
proteasome endopeptidase complex
10%
appetite
10%
adrenal cortex hormones
10%
adenosine triphosphate
10%
concentrating
10%
eicosapentaenoic acid
10%
ubiquitin
10%
adipose tissue
9%
somatotropin
8%
weight loss
8%
mechanism of action
7%
acetates
7%
death
7%
muscles
6%
Medicine & Life Sciences
Cachexia
79%
Proteolysis
17%
Appetite Stimulants
15%
Skeletal Muscle
14%
Megestrol Acetate
14%
Thalidomide
11%
Eicosapentaenoic Acid
11%
Cyclooxygenase Inhibitors
11%
Cannabinoids
10%
Therapeutics
10%
Proteasome Endopeptidase Complex
9%
Ubiquitin
9%
Growth Hormone
8%
Adipose Tissue
7%
Weight Loss
7%
Adrenal Cortex Hormones
7%
Adenosine Triphosphate
7%
Quality of Life
5%
Muscles
5%
Proteins
3%